News | January 24, 2025
Alivus Life Sciences delivers 12% revenue growth
EBITDA margins expand to 31.3%
EBITDA margins expand to 31.3%
The change is reflective of the company’s evolving vision aimed at further strengthening its global presence and a commitment to providing innovative solutions in the API and CDMO space
The conference featured comprehensive discussions, field visits, and knowledge-sharing sessions addressing different aspect of major NCDs
Regulatory filings underway for a third indication for darolutamide in prostate cancer, for finerenone in a common form of heart failure, and acoramidis in transthyretin amyloid
The site’s GMP Certification has been successfully renewed
This product is an oral SYK inhibitor and suppresses platelet destruction by macrophages and platelet depletion
MRX-5 is a novel benzoxazole antibiotic developed for the treatment of mycobacteria infections, particularly infections caused by non-tuberculous Mycobacteria
The report also revealed that 87% of physicians agreed that FEE recommendations would help to improve the speed of recovery
In the US, the compassionate use approvals are provided by FDA in the form of individual patient-specific expanded-access IND
The trademark rights for these brands will be transferred to Lupin by March next year.
Subscribe To Our Newsletter & Stay Updated
